Literature DB >> 22766537

Estimating quality-adjusted life years from patient-reported visual functioning.

C Browne1, J Brazier, J Carlton, Y Alavi, M Jofre-Bonet.   

Abstract

PURPOSE: Glaucoma is an important disease, the impacts of which on vision have been shown to have implications for patients' health-related quality of life (HRQoL). The primary aim of this study is to estimate a mapping algorithm to predict EQ-5D and SF-6D utility values based on the vision-specific measure, the 25-item Visual Functioning Questionnaire (VFQ-25), as well as the clinical measures of visual function, that is, integrated visual field, visual acuity, and contrast sensitivity.
METHODS: Ordinary least squares (OLS), Tobit, and censored least absolute deviations were compared using data taken from the Moorfields Eye Hospital in London, to assess mapping functions to predict the EQ-5D and SF-6D from the VFQ-25, and tests of visual function. These models were compared using root mean square error (RMSE), R(2), and mean absolute error (MAE).
RESULTS: OLS was the best-performing model of the three compared, as this produced the lowest RMSE and MAE, and the highest R(2).
CONCLUSIONS: The models provided initial algorithms to convert the VFQ-25 to the EQ-5D and SF-6D. Further analysis would be needed to validate the models or algorithms.

Entities:  

Mesh:

Year:  2012        PMID: 22766537      PMCID: PMC3470057          DOI: 10.1038/eye.2012.137

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  21 in total

1.  The estimation of a preference-based measure of health from the SF-36.

Authors:  John Brazier; Jennifer Roberts; Mark Deverill
Journal:  J Health Econ       Date:  2002-03       Impact factor: 3.883

2.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

3.  Application of multi-attribute utility theory to measure social preferences for health states.

Authors:  G W Torrance; M H Boyle; S P Horwood
Journal:  Oper Res       Date:  1982 Nov-Dec       Impact factor: 3.310

4.  Developing an algorithm to convert routine measures of vision into utility values for glaucoma.

Authors:  Yasmene Alavi; Mireia Jofre-Bonet; Catey Bunce; Richard P Wormald; Ananth Viswanathan; Allen Foster; Roger Hitchings
Journal:  Ophthalmic Epidemiol       Date:  2011-10       Impact factor: 1.648

5.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

6.  A utility maximization model for evaluation of health care programs.

Authors:  G W Torrance; W H Thomas; D L Sackett
Journal:  Health Serv Res       Date:  1972       Impact factor: 3.402

7.  New visual acuity charts for clinical research.

Authors:  F L Ferris; A Kassoff; G H Bresnick; I Bailey
Journal:  Am J Ophthalmol       Date:  1982-07       Impact factor: 5.258

8.  Normal values for the Pelli-Robson contrast sensitivity test.

Authors:  M Mäntyjärvi; T Laitinen
Journal:  J Cataract Refract Surg       Date:  2001-02       Impact factor: 3.351

9.  Glaucoma's impact on quality of life and its relation to clinical indicators. A pilot study.

Authors:  M B Sherwood; A Garcia-Siekavizza; M I Meltzer; A Hebert; A F Burns; S McGorray
Journal:  Ophthalmology       Date:  1998-03       Impact factor: 12.079

10.  A comparison of the EQ-5D and SF-6D across seven patient groups.

Authors:  John Brazier; Jennifer Roberts; Aki Tsuchiya; Jan Busschbach
Journal:  Health Econ       Date:  2004-09       Impact factor: 3.046

View more
  8 in total

1.  Socio-demographic, clinical characteristics and utilization of mental health care services associated with SF-6D utility scores in patients with mental disorders: contributions of the quantile regression.

Authors:  Amélie Prigent; Blaise Kamendje-Tchokobou; Karine Chevreul
Journal:  Qual Life Res       Date:  2017-06-21       Impact factor: 4.147

2.  Mapping the disease-specific LupusQoL to the SF-6D.

Authors:  Rachel Meacock; Mark Harrison; Kathleen McElhone; Janice Abbott; Sahena Haque; Ian Bruce; Lee-Suan Teh
Journal:  Qual Life Res       Date:  2014-12-16       Impact factor: 4.147

3.  Generic and disease-specific estimates of quality of life in macular degeneration: mapping the MacDQoL onto the EQ-5D-3L.

Authors:  Padraig Dixon; Helen Dakin; Sarah Wordsworth
Journal:  Qual Life Res       Date:  2015-10-01       Impact factor: 4.147

4.  The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration.

Authors:  Stavros Petrou; Oliver Rivero-Arias; Helen Dakin; Louise Longworth; Mark Oppe; Robert Froud; Alastair Gray
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

5.  Utility Index and Patient-Reported Outcome Measures in Glaucomatous Patients Comparing with Normal Participants.

Authors:  Kulawan Rojananuangnit; Nuttawan Sudjinda
Journal:  Clin Ophthalmol       Date:  2021-02-25

6.  Preference-based disease-specific health-related quality of life instrument for glaucoma: a mixed methods study protocol.

Authors:  Sergei Muratov; Dominik W Podbielski; Susan M Jack; Iqbal Ike K Ahmed; Levine A H Mitchell; Monika Baltaziak; Feng Xie
Journal:  BMJ Open       Date:  2016-11-08       Impact factor: 2.692

7.  Orthopedic, ophthalmic, and psychiatric diseases primarily affect activity limitation for Japanese males and females: Based on the Comprehensive Survey of Living Conditions.

Authors:  Tomoya Myojin; Toshiyuki Ojima; Keiko Kikuchi; Eisaku Okada; Yosuke Shibata; Mieko Nakamura; Shuji Hashimoto
Journal:  J Epidemiol       Date:  2016-11-15       Impact factor: 3.211

8.  Patient-Reported Health-Related Quality of Life in Individuals with Inherited Retinal Diseases.

Authors:  Deborah Schofield; Joshua Kraindler; Owen Tan; Rupendra Shrestha; Diana Jelovic; Sarah West; Alan Ma; John Grigg; Robyn V Jamieson
Journal:  Ophthalmol Sci       Date:  2021-12-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.